IMEIK(SZ:300896) Xin Lang Cai Jing·2026-01-08 03:10Core Viewpoint - The stock of Aimeike has shown a mixed performance with a recent increase in price, but the company has reported a significant decline in revenue and net profit for the year 2025. Group 1: Stock Performance - On January 8, Aimeike's stock rose by 2.00%, reaching 148.25 yuan per share, with a trading volume of 315 million yuan and a turnover rate of 1.03%, resulting in a total market capitalization of 44.859 billion yuan [1] - Year-to-date, Aimeike's stock price has increased by 4.61%, with a 4.96% rise over the last five trading days, a 5.01% increase over the last 20 days, but a decline of 15.52% over the last 60 days [1] Group 2: Financial Performance - For the period from January to September 2025, Aimeike reported an operating revenue of 1.865 billion yuan, a year-on-year decrease of 21.49%, and a net profit attributable to shareholders of 1.093 billion yuan, down 31.05% year-on-year [2] - Since its A-share listing, Aimeike has distributed a total of 3.887 billion yuan in dividends, with 3.012 billion yuan distributed over the past three years [3] Group 3: Shareholder Information - As of December 31, Aimeike had 60,100 shareholders, a decrease of 2.71% from the previous period, with an average of 3,472 circulating shares per person, an increase of 2.78% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, holding 6.8295 million shares (a decrease of 151,300 shares), and Huabao CSI Medical ETF, holding 4.2589 million shares (a decrease of 802,100 shares) [3]